Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial.

ABSTRACT:

Importance

Observational data have shown that postdiagnosis exercise is associated with reduced risk of prostate cancer death. The feasibility and tumor biological activity of exercise therapy is not known.

Objective

To identify recommended phase 2 dose of exercise therapy for patients with prostate cancer.

Design, setting, and participants

This single-center, phase 1a dose-finding trial was conducted at a tertiary cancer center using a patientcentric, decentralized platform and included 53 inactive men with treatment-naive localized prostate cancer scheduled to undergo surgical resection between June 2019 and January 2023. Data were analyzed in June 2024.

Intervention

Six escalated exercise therapy dose levels ranging from 90 to 450 minutes per week of individ

SUBMITTER: Jones LW 

PROVIDER: S-EPMC11258635 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature